Skip to content

Contact
Careers

<img width="197" height="109" src="https://tffpharma.com/wp-content/uploads/2022/08/TFF-Pharmaceuticals-Logo.svg" class="custom-logo astra-logo-svg" alt="TFF Pharamceuticals Logo" decoding="async" />

About
Platform Technology
Programs
Collaborations
Resources
Investors

About
Platform Technology
Programs
Collaborations
Resources
Investors

<img width="197" height="109" src="https://tffpharma.com/wp-content/uploads/2022/08/TFF-Pharmaceuticals-Logo.svg" class="custom-logo astra-logo-svg" alt="TFF Pharamceuticals Logo" decoding="async" />

About
Platform Technology
Programs
Collaborations
Resources
Investors

Contact
Careers

Privacy Policy
Accessibility Statement

News

tff pharma investors hero

Sort by Year
Search

November 30, 2023

TFF Pharmaceuticals Appoints Catherine Lee, J.D. to Board of Directors

November 30, 2023

TFF Pharmaceuticals Appoints Michael Patane, Ph.D., to Board of Directors

November 27, 2023

TFF Pharmaceuticals to Participate in the 2023 Benchmark Discovery One-on-One Investor Conference – December 7, 2023

November 14, 2023

TFF Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update

November 8, 2023

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies with Thin Film Freezing

November 7, 2023

TFF Pharmaceuticals to Hold Third Quarter 2023 Financial and Business Results Conference Call on November 14, 2023

October 2, 2023

TFF Pharmaceuticals Congratulates our Scientific Advisory Board Member, Drew Weissman, M.D., Ph.D., for Receiving the Nobel Prize in Physiology or Medicine for his Pioneering Work Enabling the Development of mRNA COVID-19 Vaccines

September 28, 2023

TFF Pharmaceuticals to Participate in Upcoming Investor Conferences

August 23, 2023

TFF Pharmaceuticals to Participate in the H.C. Wainwright 25th Annual Global Investment Conference – September 11-13, 2023

August 17, 2023

TFF Pharmaceuticals Announces Closing of $5.7 Million Public Offering of Common Stock, Including Full Exercise of Over-Allotment Option

IR Contact Information

Corey Davis, Ph.D.
LifeSci Advisors
Tel: +212-915-2577
cdavis@lifesciadvisors.com

Bill Begien

TFF Pharmaceuticals, Inc.

bbegien@tffpharma.com

Email Alerts Sign-Up

Email

SEC Filings

Press Releases

End of Day Stock Quote

Company

About
Management Team
Board of Directors
Scientific Advisory Board
Careers
Contact

Technology

Platform Technology
Thin Film Freezing Process
Platform Benefits
Pipeline
Internal Pipeline

Partnering

Collaborations
Focus Areas
Pharma
Academic
Government
CDMO
FCOI Policy

Investors

Overview
News
Events
SEC Filings
Corporate Governance
Stock Information
FAQs

Copyright © 2023 TFF Pharmaceuticals

Privacy Policy
Accessibility Statement